Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 20/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.71 |
| ▸ | CNR2 | P34972 | 3/20 | 0.71 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.53 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3519971 | 0.89 | CNR1 (0.68) | CNR1KCNH2CNR2 | |
| SCHEMBL3517298 | 0.84 | CNR1 (0.74) | CNR1KCNH2CNR2 | |
| SCHEMBL13255242 | 0.84 | CNR1 (0.80) | CNR1KCNH2CNR2CYP1A1CYP2C8 | |
| SCHEMBL13255238 | 0.83 | CNR1 (1.00) | CNR1KCNH2CNR2 | |
| SCHEMBL3522041 | 0.83 | CNR1 (0.74) | CNR1KCNH2CNR2CYP1A1CYP2C8 | |
| SCHEMBL13255240 | 0.83 | CNR1 (0.78) | CNR1KCNH2CNR2 | |
| SCHEMBL3518773 | 0.82 | CNR1 (0.83) | CNR1KCNH2CNR2 | |
| SCHEMBL3518476 | 0.81 | CNR1 (0.72) | CNR1KCNH2CNR2 | |
| SCHEMBL3518618 | 0.80 | CNR1 (0.85) | CNR1KCNH2CNR2CYP1A1CYP2C8 | |
| SCHEMBL13255239 | 0.80 | CNR1 (0.86) | CNR1KCNH2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763732-B2 | 7-Chloro-3-({5-[N-(morpholin-1-ylcarboxamido)methyl]aminomethyl}-([1,2,4]-thiadiazol-3-yl))-1-(tetrahydropyran-4-yl)methyl-1H-indole, hydrochloride salt; treatment of pain | N.V. ORGANON (NL) | 2010-07-27 | — | — | US | claimed |
| US-20070082931-A1 | Indole derivatives | AKZO NOBLE N.V. (NL) | 2007-04-12 | — | — | US | claimed |
| EP-1919471-B1 | (INDOL-3-YL)-HETEROCYCLE DERIVATIVES AS AGONISTS OF THE CANNABINOID CB1 RECEPTOR | MERCK SHARP & DOHME (NL) | 2014-01-08 | — | — | EP | disclosed |
| US-7763732-B2 | 7-Chloro-3-({5-[N-(morpholin-1-ylcarboxamido)methyl]aminomethyl}-([1,2,4]-thiadiazol-3-yl))-1-(tetrahydropyran-4-yl)methyl-1H-indole, hydrochloride salt; treatment of pain | N.V. ORGANON (NL) | 2010-07-27 | — | — | US | disclosed |
| US-20070082931-A1 | Indole derivatives | AKZO NOBLE N.V. (NL) | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082931-A1 | Indole derivatives | IDO1, TPH1, IDO2 | CNR1 36/4885KCNH2 1569/4885CNR2 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.